CVE-2021-26726 | BDVDB-2026-170146 Detail

Valmet DNAValmet DNA

Description#

A remote code execution vulnerability affecting a Valmet DNA service listening on TCP port 1517, allows an attacker to execute commands with SYSTEM privileges This issue affects: Valmet DNA versions from Collection 2012 until Collection 2021.

Impact#

Per CVSS v3.1: confidentiality impact high, integrity impact high, availability impact high. Attack vector: adjacent.

Weaknesses#

CWE-305 Authentication Bypass by Primary Weakness
CWE-209 Information Exposure Through an Error Message
CWE-272 Least Privilege Violation
CWE-78 Improper Neutralization of Special Elements used in an OS Command ('OS Command Injection')

References#

Exploit#

No public exploit known

History#

Version 12022-02-16Record published in the CVE List.
Version 22024-09-17Most recent update recorded in the CVE List.

Published

Published: 2022-02-16
Last modified: 2024-09-17

Vendor information

Vendor: Valmet DNA
Product: Valmet DNA

All Valmet DNA vulnerabilities

Score

8.8 High

EPSS

1.1%, Low

Estimated chance of exploitation in the next 30 days. EPSS percentile: 67.1.

KEV

Not listed in the CISA Known Exploited Vulnerabilities catalog.

Impact

Command Injection

Action

No specific action is recorded in the source data. Check the references for vendor guidance.

Affected Systems

Vulnerable
>= Collection 2012 and < Collection 2021
Fixed
Collection 2021

Scoring System

CVSS v4.0

Not available

CVSS v3.1

8.8 High

CVSS:3.1/AV:A/AC:L/PR:N/UI:N/S:U/C:H/I:H/A:H

Metric breakdown
Attack Vector	Adjacent
Attack Complexity	Low
Privileges Required	None
User Interaction	None
Scope	Unchanged
Confidentiality	High
Integrity	High
Availability	High

CVSS v3.0

Not available

CVSS v2

Not available

Source: CVE List v5 (record); CISA KEV (kev, action); FIRST EPSS (epss).